Sung Chul Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sung Chul Hwang has a total of 282 co-authors. Here are the top co-authors by number of shared publications:
Kwang Joo Park
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Korea
24 shared publicationsSeung Soo Sheen
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Korea
23 shared publicationsYoon Jung Oh
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
22 shared publications- Kwang Joo Park
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
14 shared publications Keu Sung Lee
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Korea
13 shared publicationsYi Hyeong Lee
Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon 442-721, South Korea
11 shared publications
Latest Publications
- 1 January 2020
- Published by Elsevier in Respiratory Investigation
- Vol. 58 (1) , 45-51
Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation
- 1 January 2020
- Published by Elsevier in Respiratory Investigation
- Vol. 58 (1) , 45-51
Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation
- 28 December 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (1) , 90-96
Antimetastatic Activity of Gallic Acid‐conjugated Chitosan against Pulmonary Metastasis of Colon Carcinoma Cells
We synthesized gallic acid (GA)‐conjugated chitosan (abbreviated as chitogallate) to study its antitumor activity against CT26 mouse colorectal carcinoma cells. GA was conjugated with chitosan by aid of water‐soluble carbodiimide. Chitogallate nanoparticles were prepared by dialysis method, and these nanoparticles have spherical shapes with sizes ranged about 70–250 nm. Chitogallate nanoparticles have superior antioxidants activities as well as GA itself. At cytotoxicity study, GA showed dose‐dependent cytotoxicities against CCD986sk cells and CT26 cells while chitogallate nanoparticles were not significantly affected to the viability of cells. In Matrigel invasion assay, chitogallate nanoparticles have superior anti‐invasive capacity against cancer cells as well as GA itself, i.e., invasiveness of CT26 cells was decreased according to GA contents in chitogallate nanoparticles. Furthermore, gelatin zymography also showed that chitogallate nanoparticles having higher substitution degree of GA decreased matrix metalloproteinase‐2 activity. Chitogallate nanoparticles efficiently inhibited pulmonary metastasis of CT26 cells in animal pulmonary metastasis model. We prepared chitogallate nanoparticles for application as an anti‐invasive agent. Chitogallate nanoparticles were less toxic than GA itself and have superior anti‐invasive/antimetastatic activity. We suggest that chitogallate nanoparticles are promising candidate for inhibition of tumor invasion/metastasis.
- 28 December 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (1) , 90-96
Antimetastatic Activity of Gallic Acid‐conjugated Chitosan against Pulmonary Metastasis of Colon Carcinoma Cells
We synthesized gallic acid (GA)‐conjugated chitosan (abbreviated as chitogallate) to study its antitumor activity against CT26 mouse colorectal carcinoma cells. GA was conjugated with chitosan by aid of water‐soluble carbodiimide. Chitogallate nanoparticles were prepared by dialysis method, and these nanoparticles have spherical shapes with sizes ranged about 70–250 nm. Chitogallate nanoparticles have superior antioxidants activities as well as GA itself. At cytotoxicity study, GA showed dose‐dependent cytotoxicities against CCD986sk cells and CT26 cells while chitogallate nanoparticles were not significantly affected to the viability of cells. In Matrigel invasion assay, chitogallate nanoparticles have superior anti‐invasive capacity against cancer cells as well as GA itself, i.e., invasiveness of CT26 cells was decreased according to GA contents in chitogallate nanoparticles. Furthermore, gelatin zymography also showed that chitogallate nanoparticles having higher substitution degree of GA decreased matrix metalloproteinase‐2 activity. Chitogallate nanoparticles efficiently inhibited pulmonary metastasis of CT26 cells in animal pulmonary metastasis model. We prepared chitogallate nanoparticles for application as an anti‐invasive agent. Chitogallate nanoparticles were less toxic than GA itself and have superior anti‐invasive/antimetastatic activity. We suggest that chitogallate nanoparticles are promising candidate for inhibition of tumor invasion/metastasis.
- 1 January 2014
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 18 (1) , 109-116
Unique features of non-obstructive emphysema and pure airway obstruction
SETTING: Emphysema without airway obstruction or airway obstruction without emphysema are often detected clinically, although they are commonly co-existent. We therefore tested the hypothesis that non-obstructive emphysema and pure airway obstruction have unique features. METHODS: A case-control observation study was undertaken retrospectively in a patient cohort at a single centre. Among 2662 subjects who underwent chest computed tomography and pulmonary function tests, we enrolled 90 patients with non-obstructive emphysema, 119 with pure airway obstruction, 81 with obstructive emphysema and 2031 subjects as normal controls. The features of the four groups were analysed and compared. RESULTS: Higher serum homocysteine (13.4 ± 7.4 vs. 11.6 ± 4.6 mol/l), higher rate of osteoporosis (15.8% vs. 4.5%), higher leukocyte count, higher male ratio, lower serum albumin and lower body mass index were observed in subjects with non-obstructive emphysema than in controls (P P CONCLUSION: Hyperhomocysteinaemia, hypoalbuminaemia, osteoporosis and higher leukocyte count were independent predictors of non-obstructive emphysema.
- 1 January 2014
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 18 (1) , 109-116
Unique features of non-obstructive emphysema and pure airway obstruction
SETTING: Emphysema without airway obstruction or airway obstruction without emphysema are often detected clinically, although they are commonly co-existent. We therefore tested the hypothesis that non-obstructive emphysema and pure airway obstruction have unique features. METHODS: A case-control observation study was undertaken retrospectively in a patient cohort at a single centre. Among 2662 subjects who underwent chest computed tomography and pulmonary function tests, we enrolled 90 patients with non-obstructive emphysema, 119 with pure airway obstruction, 81 with obstructive emphysema and 2031 subjects as normal controls. The features of the four groups were analysed and compared. RESULTS: Higher serum homocysteine (13.4 ± 7.4 vs. 11.6 ± 4.6 mol/l), higher rate of osteoporosis (15.8% vs. 4.5%), higher leukocyte count, higher male ratio, lower serum albumin and lower body mass index were observed in subjects with non-obstructive emphysema than in controls (P P CONCLUSION: Hyperhomocysteinaemia, hypoalbuminaemia, osteoporosis and higher leukocyte count were independent predictors of non-obstructive emphysema.
- Open Access
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (11) , 1572-1576
Prevention of Venous Thromboembolism in Medical Intensive Care Unit: A Multicenter Observational Study in Korea
Lee J, et al. J Korean Med Sci. 2014 Nov;29(11):1572-1576. https://doi.org/10.3346/jkms.2014.29.11.1572
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (11) , 1572-1576
Open AccessPrevention of Venous Thromboembolism in Medical Intensive Care Unit: A Multicenter Observational Study in Korea
Lee J, et al. J Korean Med Sci. 2014 Nov;29(11):1572-1576. https://doi.org/10.3346/jkms.2014.29.11.1572
- 1 September 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (15) , 1808-1819
GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) β1-induced senescence
- 1 September 2012
- Published by Elsevier in Experimental Cell Research
- Vol. 318 (15) , 1808-1819
GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) β1-induced senescence
- Open Access
- 31 August 2012
- Published by Korean Society of Ocean Engineers (KISTI) in Journal of Ocean Engineering and Technology
- Vol. 26 (4) , 50-56
Effect on Vessel Motion Caused by Mitigation of Sloshing Impact Loads using Floaters
- 31 August 2012
- Published by Korean Society of Ocean Engineers (KISTI) in Journal of Ocean Engineering and Technology
- Vol. 26 (4) , 50-56
Open AccessEffect on Vessel Motion Caused by Mitigation of Sloshing Impact Loads using Floaters
- Open Access
- 1 January 2012
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 73 (3) , 151-161
The Significance of Sedation Control in Patients Receiving Mechanical Ventilation
Jung YJ, et al. Tuberc Respir Dis. 2012 Sep;73(3):151-161. http://dx.doi.org/10.4046/trd.2012.73.3.151
- 1 January 2012
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 73 (3) , 151-161
Open AccessThe Significance of Sedation Control in Patients Receiving Mechanical Ventilation
Jung YJ, et al. Tuberc Respir Dis. 2012 Sep;73(3):151-161. http://dx.doi.org/10.4046/trd.2012.73.3.151
- 1 June 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (11) , 1561-1568
Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized Trial
Rationale: Severe community-acquired pneumonia (sCAP) is a leading cause of death worldwide. Adjunctive therapies for sCAP are needed to further improve outcome. A systemic inhibitor of coagulation, tifacogin (recombinant human tissue factor pathway inhibitor) seemed to provide mortality benefit in the sCAP subgroup of a previous sepsis trial. Objectives: Evaluate the impact of adjunctive tifacogin on mortality in patients with sCAP. Methods: A multicenter, randomized, placebo-controlled, double-blind, three-arm study was conducted from July 2005 to June 2008 at 188 centers in North and South America, Europe, South Africa, Asia, Australia, and New Zealand. Adults with sCAP were randomized to receive a continuous intravenous infusion of tifacogin 0.025 mg/kg/h, tifacogin 0.075 mg/kg/h, or matching placebo over 96 hours. Measurements and Main Results: Severity-adjusted 28-day all-cause mortality. Of 2,138 randomized patients, 946, 238, and 918 received tifacogin 0.025 mg/kg/h, tifacogin 0.075 mg/kg/h, and placebo, respectively. Tifacogin 0.075 mg/kg/h was discontinued after the first interim analysis according to prespecified futility criterion. The 28-day all-cause mortality rates were similar between the 0.025 mg/kg/h (18%) and placebo groups (17.9%) (P = 0.56). Greater reduction in prothrombin fragment 1+2 and thrombin antithrombin complexes levels relative to baseline throughout the first 96 hours was found with tifacogin 0.025 mg/kg/h than with placebo. The incidence of adverse events and serious adverse events were comparable between the tifacogin 0.025 mg/kg/h and placebo groups. Conclusions: Tifacogin showed no mortality benefit in patients with sCAP despite evidence of biologic activity.
- 1 June 2011
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (11) , 1561-1568
Recombinant Tissue Factor Pathway Inhibitor in Severe Community-acquired Pneumonia: A Randomized Trial
Rationale: Severe community-acquired pneumonia (sCAP) is a leading cause of death worldwide. Adjunctive therapies for sCAP are needed to further improve outcome. A systemic inhibitor of coagulation, tifacogin (recombinant human tissue factor pathway inhibitor) seemed to provide mortality benefit in the sCAP subgroup of a previous sepsis trial. Objectives: Evaluate the impact of adjunctive tifacogin on mortality in patients with sCAP. Methods: A multicenter, randomized, placebo-controlled, double-blind, three-arm study was conducted from July 2005 to June 2008 at 188 centers in North and South America, Europe, South Africa, Asia, Australia, and New Zealand. Adults with sCAP were randomized to receive a continuous intravenous infusion of tifacogin 0.025 mg/kg/h, tifacogin 0.075 mg/kg/h, or matching placebo over 96 hours. Measurements and Main Results: Severity-adjusted 28-day all-cause mortality. Of 2,138 randomized patients, 946, 238, and 918 received tifacogin 0.025 mg/kg/h, tifacogin 0.075 mg/kg/h, and placebo, respectively. Tifacogin 0.075 mg/kg/h was discontinued after the first interim analysis according to prespecified futility criterion. The 28-day all-cause mortality rates were similar between the 0.025 mg/kg/h (18%) and placebo groups (17.9%) (P = 0.56). Greater reduction in prothrombin fragment 1+2 and thrombin antithrombin complexes levels relative to baseline throughout the first 96 hours was found with tifacogin 0.025 mg/kg/h than with placebo. The incidence of adverse events and serious adverse events were comparable between the tifacogin 0.025 mg/kg/h and placebo groups. Conclusions: Tifacogin showed no mortality benefit in patients with sCAP despite evidence of biologic activity.
- Open Access
- 1 January 2011
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 70 (1)
Evaluation of Respiratory Parameters in Patients with Acute Lung Injury Receiving Adaptive Support Ventilation
- 1 January 2011
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 70 (1)
Open AccessEvaluation of Respiratory Parameters in Patients with Acute Lung Injury Receiving Adaptive Support Ventilation